Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.
Sikander Ailawadhi, MD, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses the integration of selinexor (Xpovio) into the treatment landscape of relapsed/refractory multiple myeloma.
In July 2019, the FDA granted an accelerated approval to selinexor in combination with dexamethasone for the treatment of patients with heavily pretreated relapsed/refractory multiple myeloma. The FDA indication recommends that patients receive 80 mg of selinexor twice weekly, says Ailawadhi.
However, the field has largely adopted a once-weekly dosing regimen with selinexor, Ailawadhi explains. Additionally, the combination of once-weekly selinexor with dexamethasone and bortezomib (Velcade) has been utilized, although it is not indicated in the approval, concludes Ailawadhi.